Naomi van den Berg, Postdoctoral Fellow Mathematical Modelling Cancer Dynamics at The Francis Crick Institute, shared a post on LinkedIn:
“New review is officially out today in Annual Reviews Cancer Biology! Authored together with Samra Turajlić and Charles Swanton.
How do cancers evolve, and how can we track that evolution in real time?
In “TRACERx as an Optimized Paradigm for Understanding Cancer Evolution” (Annual Review of Cancer Biology), we bring together insights from the TRACERx lung and renal programmes to explore this question.
We discuss how combining multiregion sampling, longitudinal follow-up, and multiomic profiling has revealed:
- The central role of intratumour heterogeneity;
- The importance of immune and microenvironmental interactions;
- And that evolution extends well beyond DNA.
One thing that really stood out to me while working on this review was the sheer scale and multimodality required to even begin answering how cancer evolves. The figure below captures this: mapping the layers of data, methods, and analyses needed to connect tumour biology to clinical outcomes.
TRACERx provides a powerful framework for linking evolutionary dynamics to patient care, and for shaping the next generation of cancer research.
Grateful for the support that made this work possible, and especially to the patients who contributed to the TRACERx studies.”
To which Samra Turajlić, Director and Group Leader at Cancer Research UK Manchester Institute, added:
“Congratulations Naomi van den Berg, PhD on this review! > 10 years since Tx programmes have started to map out key steps in cancer evolution – they continue to teach us so much!”
Title: TRACERx as an Optimized Paradigm for Understanding Cancer Evolution
Authors: Naomi Iris van den Berg, Charles Swanton and Samra Turajlic.
Other articles featuring Naomi van den Berg and Samra Turajlić on OncoDaily.